Next Phase Newsletter

This Western Europe-based investment firm has been active for over two decades and manages multi-billion in assets under management. The firm takes a sector-agnostic approach, investing across a broad spectrum including enterprise software, fintech, consumer technologies, deeptech, and life sciences. 

Typical equity investments range from $1 million to $10 million, and the firm expects to make several new investments annually. While companies must maintain a local operational presence in the firm’s home country, they may also have international footprints. 

In the life sciences and biotech space, the firm adopts a wide-angle lens, looking for companies developing drug discovery platforms, synthetic biology innovations, and enabling research technologies.  

The firm is open to investing in pre-revenue companies, and is supportive of both emerging and experienced founding teams. It frequently invests at the early growth stage, often in syndicate with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 
This venture capital firm focuses on breakthrough technologies transforming healthcare and typically invests at the pre-seed, seed, and pre-Series A stages. The firm is backed by limited partners from within the healthcare industry, reinforcing its domain expertise and strategic alignment with clinical innovation. 

The firm targets early-stage life science startups working at the intersection of cutting-edge science and healthcare applications. Areas of interest include genomic technologies, synthetic biology, digital health, machine learning and artificial intelligence, therapeutics, and diagnostics. In therapeutics, the firm focuses on pre-IND assets, while for technologies regulated as medical devices, the firm prioritizes smart devices at the pre-commercial stage. 

With a team that brings a strong clinical perspective, the firm actively supports its portfolio companies through clinical development and has a history of helping academic scientists translate research into commercial ventures. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An angel syndicate is focused on life science tools and biotech infrastructure. The firm has a concentrated investment strategy targeting U.S.-based companies from the Pre-Seed to Series A stages. The firm’s investor base includes a select group of limited partners, about half of whom are active operators within the life science tools sector. The firm can co-invest but prefers to lead investments, with typical check sizes ranging from $160K to $2M. The firm brings deep domain expertise in life sciences and works closely with founders to build companies, pairing them with strategic capital. The firm is thesis-driven and leverages its extensive operator network, commercial reach, and M&A experience to accelerate company growth and strategy. The firm supports all aspects of business development, from financial modeling and strategic planning to connecting founders with key industry stakeholders within the life sciences ecosystem. 

The firm exclusively targets life science tools, software, biotech infrastructure, and platform technologies that typically include a consumable component. The firm does not invest in therapeutics, diagnostics, digital health, or any business requiring FDA clearance. The firm is open to all development stages and all classes of tools, software, and platform technologies. 

The firm only works with companies whose founders and teams are fully dedicated to their ventures. The firm generally prefers to take a board seat if it leads the investment round and if doing so aligns with the company’s stage of development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

Founded in 2021, an early-stage venture capital firm based in Western Europe invests in multiple verticals. Within life science and healthcare, the firm focuses on medtech and digital health. The sweet point for the firm is pre-seed. Initial investment is typically around €600K, with the potential for follow-on investment of another €600K Euro. The firm is open to opportunities globally with no geographical restrictions. While the firm is open to both leading and co-investing in rounds, the firm would prefer if there is a lead investor in place. 
 
Within life science and healthcare, the firm is focused on medtech and digital health, and is opportunistic in subsectors and indications. Some areas of interest are: surgical devices and cardiovascular diseases. For the stage of development, the firm is open to investing in the preclinical stage, but would prefer companies that have prototypes. 
 
There is no specific requirement for the company’s management team. The firm is interested in working with experienced entrepreneurs. The firm is an active investor and will consider observer seats on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An investment firm based in the Middle East is a premier investment company with a diverse portfolio spanning multiple asset classes, including real assets and alternative investments. The firm’s vision is to become a leading integrated solutions provider in cell and gene therapy, establishing itself as the first globally trusted partner in precision medicine within the Middle East. The firm focuses on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5–10M. In alignment with national strategic initiatives, the firm aims to act as a catalyst for developing this vital industry and emphasizes the importance of the private sector in supporting emerging, innovative sectors. The firm aspires to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases while contributing to the localization of the biotechnology industry and building national expertise to achieve these ambitious goals. 

Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1, and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For tech-driven biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development. 

The firm is only interested in companies willing to work toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve-out or partnership in the region is necessary. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A specialized venture fund with a single limited partner leverages deep expertise in transfusion medicine, cell therapy, and hematology. The firm launched a fund dedicated to early-stage life science investments from Series A to C and has made multiple investments to date. While primarily focused on U.S.-based companies, the firm remains open to global opportunities. 

The firm has four key areas of focus: benign hematology, transfusion medicine, cell therapy, and infectious diseases. The firm is open to therapeutics, diagnostics, and medical devices. Within therapeutics, the firm considers most modalities and prefers programs that are clinical stage or near-clinical stage (IND-ready or submitted). Within diagnostics, the firm prefers technologies at the clinical stage or on the market, with proof of concept demonstrated. Within medical devices, the firm is open to all technologies but is particularly interested in cell therapy-enabling technologies at the clinical stage or on the market, with proof of concept established. With a focus on the need for blood-related and cellular technologies, the firm seeks investments that not only generate financial returns but also align with a humanitarian mission to advance healthcare access and innovation. 

The firm values working with management teams that are fully committed to their projects. The firm prefers teams with a balanced mix of scientific and commercial expertise and takes a collaborative approach as a strategic co-investor, engaging closely with the subject-matter experts within each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology